Share on StockTwits

Insulet (NASDAQ:PODD) is scheduled to be announcing its Q214 earnings results on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $72.94 million for the quarter.

Shares of Insulet (NASDAQ:PODD) traded down 0.28% on Wednesday, hitting $35.39. 283,262 shares of the company’s stock traded hands. Insulet has a 52 week low of $30.18 and a 52 week high of $51.31. The stock has a 50-day moving average of $37.85 and a 200-day moving average of $40.98. The company’s market cap is $1.961 billion.

A number of analysts have recently weighed in on PODD shares. Analysts at Barrington Research upgraded shares of Insulet from a “market perform” rating to an “outperform” rating in a research note on Thursday, May 15th. They now have a $40.00 price target on the stock. On the ratings front, analysts at Jefferies Group cut their price target on shares of Insulet from $60.00 to $50.00 in a research note on Friday, May 9th. Finally, analysts at Leerink Swann cut their price target on shares of Insulet from $55.00 to $45.00 in a research note on Friday, May 9th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $45.73.

In other Insulet news, CEO Duane Desisto sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $34.23, for a total value of $684,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Insulet Corporation is primarily engaged in the development, manufacturing and sale of its OmniPod Insulin Management System (NASDAQ:PODD).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.